Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4439418 | 0.99 | PTGS2 (0.33) | PTGS2PTGS1IDO1ALDH1A1MEN1 | |
| SCHEMBL3688649 | 0.86 | PTGS2 (0.40) | PTGS2PTGS1IDO1ALDH1A1MEN1 | |
| SCHEMBL3691252 | 0.85 | ALDH1A1 (0.34) | IDO1ALDH1A1MEN1KMT2ASLC6A4 | |
| Hydrochloric Acid SCHEMBL4439413 | 0.85 | IDO1 (0.41) | PTGS2PTGS1IDO1ALDH1A1MEN1 | |
| Bromide SCHEMBL4445152 | 0.84 | ALDH1A1 (0.33) | IDO1ALDH1A1KMT2ASLC6A4ALDH3A1 | |
| SCHEMBL3686879 | 0.83 | IDO1 (0.42) | PTGS2PTGS1IDO1ALDH1A1MEN1 | |
| SCHEMBL3688893 | 0.82 | IDO1 (0.41) | IDO1ALDH1A1MEN1KMT2A | |
| Bromide SCHEMBL4439229 | 0.82 | PTGS2 (0.41) | PTGS2PTGS1IDO1ALDH1A1MEN1 | |
| Bromide SCHEMBL4448371 | 0.81 | IDO1 (0.40) | IDO1ALDH1A1MEN1KMT2A | |
| SCHEMBL3687316 | 0.81 | IDO1 (0.35) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061754-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-05-27 | — | — | EP | claimed |
| WO-2008115999-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | WO | claimed |
| US-20080234384-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | US | claimed |
| WO-2010005851-A1 | COMBINATION THERAPY FOR TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2010-01-14 | — | — | WO | disclosed |
| US-20080234384-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234384-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | FECH, SLC10A1, SLC40A1 | PTGS2 1538/4885PTGS1 1620/4885IDO1 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.